Sarsia Seed AS is a Norwegian Seed Capital Fund which invests in Norwegian early phase technology companies within the energy/cleantech and biotechnology/life science sectors.

 


The fund has a total capital of 333.5 million NOK (approx, 40 mEUR/50 mUSD) and is managed by Sarsia Seed Management AS. The management company advises the Fund board regarding investment decisions. The Fund’s duration is expected to be 12 (+3) years.

 

The Management Team’s strength lay in its competence, experience and extensive national and international network of industrial players and co-investors. The Team’s collective experience comprises an optimal balance between operations, business and specialised technology know-how, applied research, and entrepreneurship; elements which are actively used both in the vetting and follow-up of investments.  

 

If you have an idea or technology which falls within our field of investments and require funding and expertise, then we encourage you to get in touch.

 

Sarsia Seed Management We are constantly on the look out for qualified people for key positions in our portfolio companies. If you feel that you have qualities which qualify you as such a candidate then please get in touch.

Sarsia Seed is part of a larger commercialisation and investment cluster located at the VilVite Centre which is a science discovery centre for the promotion of science and technology in Bergen.

Read More

NEWS

WindSim AS Introduces WindSim Version 5.1

Read more

 

Prophylix Pharma project receives EU-support

Read more

 

APIM Therapeutics covered by BioCentury

Read more

 

Geneseque raises € 1 mill

Read more

 

Important publication in Volusense

Read more

 

SeaHawk Navigation i media

Read more

 

Three Sarsia Seed portfolio companies to present at high-profiled conference

Read more

 

Vaccibody in the press

Read more

 

Share issue in Avexxin receives international attention

Read more

 

BerGen Bio in main Norwegian business Newspaper

Read more

 

Sarsia Seed invests € 1.17 mill in biotech company BerGen Bio AS

Read more

 

APIM Therapeutics selected to present at  BIO-Europe

Spring® 2012

Read more

 

Sarsia Seed completes second installment of series A funding in Avexxin AS

Read more

 

Sarsia Seed presented in Oslo Bio Update

Read more

 

Isentio receives € 330.000 for project with reference customer

Read more

 

BerGen Bio given extended coverage in Oslo Bio Update

Read more

 

Weyland in biotech publication

Read more

 

BerGen Bio initiates preclinical development of new compound for cancer treatment

Read more

 

National Norwegian study involving Isentio-technology

Read more

 

Prophylix Pharma in major Norwegian business newspaper

Read more

 

WindSim one of Norway´s most rapidly growing technology companies

Read more

 

Sarsia Seed invests further in APIM AS

Read more

 

Sarsia Seed in offshore.no

Read more

 

Vaccibody-consortium receives EUR 30 mill from the EU commission

Read more

Prophylix Pharma receives ”orphan drug” designation

Read more

BerGen Bio and Vaccibody gain attention at international cancer conference

Read more

New CEO in Sea-Hawk Navigation
Read more

Weyland to present at international biofuel conference

Read more

 

International cancer expert new on the board of BerGen Bio

Read more

 

Delante Health signs agreement with DSM

Read more

 

WindSim fronted by energy giant

Read more

 

WindSim in New Scientist

Read more


Important scientific publication in Volusense

Read more

 

Prophylix Pharma signs agreement with major Norwegian Hospitals

Read more

 

ScreenCancer screening in Norwegian Boots Pharmacies

Read more

 

Isentio launches new diagnostic product

Read more

 

Vaccibody CEO to give Keynote Speech at 2011 World Vaccine Congress in Lyon

Read more

 

Paper on Isentio-technology accepted

Read more

 

Isentio on Genomeweb

Read more

 

Statoil gives Sorbwater recognition

Read more

 

Sarsia Seed makes new round of funding in APIM Therapeutics AS

Read more

 

Weyland to present at Cleantech Capital Day

Read more

 

iSentio opens office in Silicone Valley

Read more

 

Sea-Hawk Navigation attacts international attention

Sarsia Seed's investment in BerGen Bio picked up by international media

Read more

 

BerGen Bio –founder receives innovation prize

Read more

 

Norwegian pharma-pipeline soars

Read more

 

Innovation prize to Hepmarin

Read more

 

Sorbwater to the final in Nordic Cleantech Open

Read more


Sarsia Seed leads new round of funding in Avexxin AS
Read more

iSentio-investment attracts international attention

Read more

 

Sarsia Seed invests in iSentio AS

Read more

 

BerGenBio finalist in European Venture Contest

Read more

 

BerGenBio and Vaccibody have been selected to present at Sigma Fondene’s and DnBNOR Markets’ Nordic Healthcare Conference 2010 (Venture Session)

Read more

 

BerGenBio was selected as one of the 2010 European Venture Contest’s TOP 100 companies and one of the Nordic Top 10 on the Nordic Venture Forum i København

Read more

 

BerGenBio has renewed one of it’s CRO contracts with a TOP 10 Pharma company for the third consecutive year.

Read more

 

Sarsia Seed to arrange patent seminar in co-operation with Norwegian Industrial Property Office

Read more

 

Publication in Hepmarin AS

Read more

 

BerGenBio seeks Research Assistant – Cancer (PhD Studentship)

Read more

 

BOOTS Pharmacies offer skin cancer screening in Norway in cooperation with ScreenCancer AS

Read more

 

Sorbwater AS clenses contaminated oilwater
Read more

 

WindSim and 3TIER today announced the completion a joint wind resource assessment initiative

Read more

 

WindSim and IntermapTechnologies combine advanced technologies

Read more

 

Sarsia Seed takes a stake in APIM Therapeutics AS

Read more

 

Good news for Vaccibody - FDA approves Provenge

Read more

 

Sarsia Seed invests in BerGen Bio AS

Read more

 

Sorbwater AS nominated for innovation prize

Read more

 

Weyland AS nominated for Norwegian Innovation Prize

Read more

 

Sarsia Seed invests in C10 Pharma AS

Read more

 

Sarsia Seed invests in Prophylix Pharma AS

Read more

 

Vaccibody featured  in Finansavisen

Read more

 

WindSim featured in North American Windpower

Read more

 

WindSim participated in the Bolund blind

Read more

 

Vaccibody gets thorough coverage in”Genialt nr 4 – 2009”

Read more

 

Vaccibody in project looking at the development of possibly the world’s first vaccine against food allergy.

Read more

 

Sorbwater featured in Finansavisen

Read more

 

Weyland gets extensive coverage in Bergen’s  main  local daily newspaper, Bergensavisen.

Read more

 

Weyland gets broad coverage in one of  Norway’s main financial newspapers, Finansavisen.

Read more


Sorbwater honoured with  ”Best Company Presentation Award”  and voted  “Most Promising Company” at  the  CONNECT Nordic Cleantech Partnerforum 2. desember 2009 i Bergen.

Read more


Vaccibody gets broad coverage in Genetic Engineering.

Read more

 

Hepmarin AS receives grant

Read more

 

Windsim launches new web

Read more

 

New Chief Executive Officer at Sorbwater Technology AS

Read more

 

Vaccibody presents results from  new influenza studies

Read more

 

Weyland gets local broadsheet coverage in Bergens Tidende Friday oktober 9, 2009

Read more

 

New Chief Executive Officer and Strengthened Board of Directors at Weyland AS

Read more

 

Vaccibody AS comprehensive coverage in Dagens Næringsliv

Read more

 

Vaccibody AS making headlines

Read more

 

Sarsia Seed has invested NOK 2 mill (€ 250.000) in the company Vaccibody.

Read more

 

WindSim and AXYS Join Forces to help Offshore Wind Developers

Read more

 

Weyland is strengthening it`s organization and is recruting a CEO.

Read more

 

Volusence  has received € 740.000 as a grant from Innovation Norway.

Read more

 

WindSim Launches US Subsidiary to Meet Increased Demand in the Wind Energy Industry

Appoints Software Industry Veteran Robert D. Buckley as President

Read more